FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
16.0 pts (24h)GeopolíticaOne-OffHealth & Medicine3m
KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
Sí 98%+16.0pt
Calidad del mercado
44 / 100
Baja calidadVolumen 24h
511 €
Liquidez
156,7 €
Baja liquidezCompra / Venta
80.0% / 88.0%
Spread
8.0 pt
Spread amplioDatos de mercado
Actualizado hace 2 minutos
17 jun 26, 21:00 UTC1 ene 27, 4:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
KalshiDid COVID-19 come from a laboratory?
Manifold MarketsWhich states will report local cases in the May 2026 Ebola Bundibugyo outbreak
Manifold MarketsWhen, where or how will Trump die?
Manifold MarketsReglas
If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Liquida mediante:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Ifinatamab deruxtecan (also called I-DXd or DS-7300) is an antibody-drug conjugate — think of it as a guided missile where a targeting protein is chemically linked to a potent cancer-killing payload.
- The targeting protein homes in on a molecule called B7-H3 (also known as CD276), which appears in unusually high amounts on the surface of many cancer cells, and once the drug locks onto that target it is pulled inside the cell and releases its toxic payload.
- In doing so, it aims to kill tumor cells more precisely than traditional chemotherapy, which attacks both healthy and cancerous cells indiscriminately.
Mercados abiertos
Geopolitics
POLYMARKETWhich party will gain most seats in Russian Parliamentary Election?
- United Russia (ER)+5.0pt75%
- New People (NL)-4.1pt21%
- Liberal Democratic Party of Russia (LDPR)-1.1pt3%
+5 resultados más
- Volumen total
- 22,2 M €
- Volumen 24h
- 470,8 mil €
POLYMARKETUS announces end of Iranian blockade by which date?
- December 31-2.3pt48.3%
- October 31-2.0pt29.3%
- September 30-4.0pt12.1%
+17 resultados más
POLYMARKETUS x Iran Effective Ceasefire begins by...? (2 week pause)
- September 30+1.0pt80%
- September 18+1.0pt75%
- September 11+6.5pt70%
+2 resultados más
POLYMARKETWill China invade Taiwan by end of 2026?
- No-0.2pt96%
- Yes+0.2pt4%
- Volumen total
- 35,3 M €
- Volumen 24h
- 100,1 mil €
POLYMARKETIsrael x Iran ceasefire continues through which date?
- July 18+0.3pt100%
- July 20+0.1pt100%
- July 22+0.5pt100%
+20 resultados más
POLYMARKETKharg Island no longer under Iranian control by which date?
- December 317%
- September 30+0.1pt1%
- July 310%
+7 resultados más
- Volumen total
- Nobel Peace Prize Winner 2026
- US-Iran nuclear deal?
- Russia x Ukraine peace talks by which date?
- Strait of Hormuz traffic returns to normal by December 31?
- Will the U.S. invade Iran before 2027?
- Bab el-Mandeb Strait effectively closed by which date?
- What will Trump say during RNC Convention (Night 2)?
- Russia x Ukraine ceasefire agreement by which date?
- Iran-Oman Hormuz Management Agreement by which date?
- Will the Iranian regime fall by September 30?
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- Kalshi cotiza Yes al 98% a fecha de 8 de septiembre de 2026.
- ¿Cuándo se resuelve FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- Está previsto que FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026) se resuelva el 1 de enero de 2027.
- ¿Cómo se liquida FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)?
- Kalshi liquida este mercado del siguiente modo: If the FDA's decision on Ifinatamab Deruxtecan by Daiichi Sankyo in 2026 is a full approval or an accelerated approval, the market resolves to Yes.